Synergy Pharmaceuticals (SGYP) Earns News Sentiment Rating of 0.05

Press coverage about Synergy Pharmaceuticals (NASDAQ:SGYP) has been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Synergy Pharmaceuticals earned a news sentiment score of 0.05 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 43.9675803366208 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:

How to Become a New Pot Stock Millionaire

Several equities research analysts recently issued reports on the company. Oppenheimer reissued a “hold” rating on shares of Synergy Pharmaceuticals in a research note on Thursday, March 1st. Zacks Investment Research lowered Synergy Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, March 1st. BidaskClub lowered Synergy Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday, February 6th. CIBC reissued a “market perform” rating on shares of Synergy Pharmaceuticals in a research note on Friday, January 5th. Finally, HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Synergy Pharmaceuticals in a research note on Thursday, February 1st. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $8.08.

SGYP stock traded up $0.03 during mid-day trading on Tuesday, hitting $1.80. 1,204,309 shares of the stock were exchanged, compared to its average volume of 5,455,883. The company has a quick ratio of 3.88, a current ratio of 4.33 and a debt-to-equity ratio of -21.05. Synergy Pharmaceuticals has a 12 month low of $1.68 and a 12 month high of $4.84. The firm has a market cap of $446.45, a P/E ratio of -1.75 and a beta of 1.17.

Synergy Pharmaceuticals (NASDAQ:SGYP) last issued its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.03. Synergy Pharmaceuticals had a negative return on equity of 652.66% and a negative net margin of 1,333.76%. The firm had revenue of $9.40 million during the quarter, compared to analyst estimates of $7.12 million. The business’s revenue for the quarter was up 840.0% on a year-over-year basis. research analysts expect that Synergy Pharmaceuticals will post -0.52 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Synergy Pharmaceuticals (SGYP) Earns News Sentiment Rating of 0.05” was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at

Synergy Pharmaceuticals Company Profile

Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.

Insider Buying and Selling by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)

Receive News & Ratings for Synergy Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply